Cannabigerol Research Points to Broad Therapeutic Potential
Cannabigerol (CBG) is attracting interest as researchers investigate cannabinoids beyond the better-known THC and CBD. A 2024 review published in Molecules examines CBG’s molecular activity and summarizes evidence linking the compound to possible effects on pain, inflammation, neurodegeneration, metabolic disorders and cancer.
CBG is a non-intoxicating phytocannabinoid produced from cannabigerolic acid, a precursor to several other cannabinoids, including THC, CBD, cannabinol and cannabichromene. Its effects appear to involve more than the classical cannabinoid receptors CB1 and CB2. Laboratory research has also examined CBG’s interactions with transient receptor potential channels, the alpha-2 adrenergic receptor, the serotonin 5-HT1A receptor and PPAR-gamma, a receptor involved in metabolism and inflammation.
This broad pharmacological profile may help explain why CBG is being studied across several areas of medicine. However, it also makes the compound’s effects more difficult to predict. Receptor activity can vary according to the dose, tissue, formulation and experimental model, and findings from one system cannot automatically be applied to patients.
Preclinical signals in pain and inflammation
Some of the most consistent interest has centered on inflammation and pain. In animal and cellular models, CBG has been associated with reduced inflammatory signaling and lower pain sensitivity. Researchers have also investigated its effects in experimental inflammatory bowel disease, including models designed to resemble aspects of Crohn’s disease and ulcerative colitis.
These findings suggest that CBG could eventually be explored as a non-opioid or adjunctive treatment for selected pain and inflammatory conditions. They do not yet establish that CBG relieves chronic pain or treats inflammatory bowel disease in people. A 2024 review of non-intoxicating cannabinoids noted that direct evidence for CBG in visceral or abdominal pain remains especially limited.
CBG has also shown antibacterial activity in laboratory studies, including effects on bacterial growth and biofilm formation. Such results may be useful for drug-discovery research, but laboratory antibacterial activity is not the same as demonstrating that a CBG product can safely treat an infection in humans.
Neuroprotection and metabolism
The Molecules review describes preclinical work examining CBG in conditions such as Parkinson’s disease, Alzheimer’s disease and multiple sclerosis. In experimental models, researchers have reported changes in motor performance, oxidative stress and neuroinflammatory markers. Proposed mechanisms include limiting inflammatory responses and protecting neurons from cell death.
Other studies have explored CBG’s possible effects on appetite, energy expenditure and body weight. By influencing cannabinoid and adrenergic signaling, CBG may affect metabolic pathways, including the activity of brown adipose tissue. These observations have prompted interest in metabolic syndrome, but they remain preliminary and should not be interpreted as evidence that CBG is an established weight-loss treatment.
Cancer findings are laboratory-based
CBG’s potential anticancer activity has been reported in experiments involving prostate cancer, colorectal cancer and glioblastoma cells. Depending on the model, researchers have observed reduced tumor-cell growth or migration, and some studies have investigated whether CBG can enhance the effects of conventional chemotherapy.
These results are hypothesis-generating rather than clinical proof. Effects seen in isolated cells may depend on concentrations that are difficult to achieve safely in the human body, and a compound that affects cancer cells in a laboratory dish may not shrink tumors in patients. The National Cancer Institute’s evidence summary states that cannabis and cannabinoids have not been approved by the U.S. Food and Drug Administration as cancer treatments. Existing clinical evidence involving cannabinoids has focused mainly on symptom management, such as chemotherapy-related nausea and vomiting—not on CBG as an anticancer drug.
The next step is human research
The central limitation of the CBG literature is its lack of clinical evidence. Much of the research summarized in the 2024 review comes from cell cultures, animal models or receptor-binding experiments. Important questions about absorption, dosing, drug interactions, long-term safety and effectiveness in specific diseases remain unanswered.
Human studies are beginning to address those gaps. For example, a registered clinical trial of full-spectrum, hemp-derived CBG was designed to examine its effects and safety in healthy adults. Studies of this kind are an early step; they cannot by themselves demonstrate that CBG treats cancer, chronic pain, neurodegenerative disease or metabolic disorders.
For now, CBG is best viewed as a promising research compound rather than a proven therapy. Its activity across several biological targets gives scientists multiple avenues to investigate, but well-designed human trials will be needed before its therapeutic value—or its risks—can be determined with confidence.
